Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Celyad Oncology Appoints Marina Udier, Ph.D., to Board of Directors
Celyad Oncology SEJanuary 11, 2021 GMT
MONT-SAINT-GUIBERT, Belgium, Jan. 11, 2021 (GLOBE NEWSWIRE) Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that Marina Udier, Ph.D., has been appointed to its Board of Directors.
“I am very pleased to welcome Marina to our Board of Directors,” stated Filippo Petti, CEO of Celyad Oncology. “As a highly regarded leader in the biopharmaceutical industry, we look forward to benefiting from Marina’s wealth of experience as we continue to advance key elements of our pipeline with the goal of developing innovative cell therapies against cancer.”
Celyad Oncology SA: Celyad Oncology Appoints Marina Udier, Ph.D., to Board of Directors
Regulatory News:
Celyad Oncology SA (Euronext Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that Marina Udier, Ph.D., has been appointed to its Board of Directors. I am very pleased to welcome Marina to our Board of Directors, stated Filippo Petti, CEO of Celyad Oncology. As a highly regarded leader in the biopharmaceutical industry, we look forward to benefiting from Marina s wealth of experience as we continue to advance key elements of our pipeline with the goal of developing innovative cell therapies against cancer.